Eli Lilly and Co (XSWX:LLY) EPS without NRI: CHF23.47 (TTM As of Mar. 2026)


XSWX:LLY Eli Lilly and Co XSWX:LLY
100 GF Score
Price CHF955.00
GF Value CHF1,114.27
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Eli Lilly and Co EPS without NRI?

Eli Lilly and Co XSWX:LLY 100 EPS without NRI is CHF23.47 as of Mar. 2026. GuruFocus rates XSWX:LLY with a GF Score™ of 100/100 and a GF Value™ of CHF1,114.27 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 784 Drug Manufacturers companies, Eli Lilly and Co ranks better than 86.73% on this metric.

Eli Lilly and Co's earnings per share without non-recurring items for the three months ended in Mar. 2026 was CHF6.73. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was CHF23.47.

During the past 12 months, Eli Lilly and Co's average earnings per share (NRI) Growth Rate was 113.90% per year. During the past 3 years, the average earnings per share (NRI) Growth Rate was 45.00% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 21.30% per year. During the past 10 years, the average earnings per share (NRI) Growth Rate was 17.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Eli Lilly and Co's EPS without NRI or its related term are showing as below:

XSWX:LLY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -27.4   Med: 12.3   Max: 49
Current: 45

During the past 13 years, Eli Lilly and Co's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 49.00% per year. The lowest was -27.40% per year. And the median was 12.30% per year.

XSWX:LLY's 3-Year EPS without NRI Growth Rate is ranked better than
86.73% of 784 companies
in the Drug Manufacturers industry
Industry Median: 9.7 vs XSWX:LLY: 45.00

Eli Lilly and Co's EPS (Diluted) for the three months ended in Mar. 2026 was CHF6.50. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was CHF22.45.

Eli Lilly and Co's EPS (Basic) for the three months ended in Mar. 2026 was CHF6.51. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was CHF22.50.


Eli Lilly and Co  (XSWX:LLY) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Eli Lilly and Co EPS without NRI Related Terms


Eli Lilly and Co EPS without NRI Historical Data

* Premium members only.

The historical data trend for Eli Lilly and Co's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eli Lilly and Co EPS without NRI Chart

Eli Lilly and Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.52 7.40 5.47 11.58 19.29

Eli Lilly and Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.95 5.15 5.59 6.01 6.73

XSWX:LLY vs JNJ, ABBV, MRK: EPS without NRI Comparison

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eli Lilly and Co PE Ratio without NRI vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's PE Ratio without NRI falls into.


XSWX:LLY
100GF Score
Eli Lilly and Co XSWX:LLY
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eli Lilly and Co EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF23.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of CHF23.47 mean?
Eli Lilly and Co (XSWX:LLY) has a EPS without NRI of CHF23.47 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Eli Lilly and Co and its competitors. According to the industry distribution chart, Eli Lilly and Co ranks #104 out of 784 companies in the Drug Manufacturers industry, placing it in the top 13.3%.
Is Eli Lilly and Co's EPS without NRI too high?
Eli Lilly and Co's current EPS without NRI is CHF23.47. Based on the distribution chart, Eli Lilly and Co ranks #104 out of 784 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Eli Lilly and Co has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's EPS without NRI compare to JNJ and ABBV?
According to the Drug Manufacturers industry distribution chart, Eli Lilly and Co ranks #104 out of 784 companies for EPS without NRI. This places Eli Lilly and Co in the top 13% of its industry — outperforming the majority of peers. The industry median EPS without NRI is 9.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Drug Manufacturers company?
The median EPS without NRI among Drug Manufacturers companies is 9.70, based on 784 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Eli Lilly and Co and its competitors. For the Drug Manufacturers industry, the median EPS without NRI is 9.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eli Lilly and Co's current EPS without NRI is CHF23.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Based on GuruFocus' analysis, Eli Lilly and Co (XSWX:LLY) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF1,114.27, compared to a current price of CHF955.00 — trading 14.3% below its estimated fair value. The current EPS without NRI is CHF23.47. Eli Lilly and Co's overall GF Score™ is 100/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Eli Lilly and Co (XSWX:LLY), the current EPS without NRI is CHF23.47 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Eli Lilly and Co (XSWX:LLY) Overvalued in 2026?

Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued. The current stock price of CHF955.00 is trading 14.3% below its estimated GF Value™ of CHF1,114.27. GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.

Key valuation signals for XSWX:LLY:

  • EPS without NRI: CHF23.47
  • GF Value™: CHF1,114.27 vs. price of CHF955.00 (14.3% below fair value)
  • GF Score™: 100/100 with 6 warning signs

No single metric tells the full story. See the XSWX:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Eli Lilly and Co Business Description

Address Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
100GF Score

Get the complete analysis for XSWX:LLY

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF955.00
Price
CHF1,114.27
GF Value